BrainTACs Enable Brain-Selective Inhibition of CNS Targets, with Reduced Peripheral Adverse Effects

• Overview Montara’s BrainOnly™ platform and how our two-drug combinations enable brain-selective pharmacology through spatially restricted induced proximity
• Detail progress on our lead asset, MTX-E1, for brain-selective mTOR inhibition
• Provide insight into expanding the platform to additional targets and indications using our heterobifunctional BrainTACs™ (Brain Targeting Chimeras) for brain-selective two-drug combinations

Speakers:

Zach Hill

Chief Technology Officer

Montara Therapeutics